Email this article Immunopathological aspects in targeted therapy of psoriasis and comorbid conditions.
- Authors: Ardalina O.1
-
Affiliations:
- ФГБОУ ВО Саратовский Государственный медицинский университет им. В.И. Разумовского Минздрава РФ
- Section: DERMATOLOGY
- Submitted: 07.04.2025
- Accepted: 28.09.2025
- Published: 17.11.2025
- URL: https://rjsvd.com/1560-9588/article/view/678188
- DOI: https://doi.org/10.17816/dv678188
- ID: 678188
Cite item
Full Text
Open Access
Access granted
Subscription or Fee Access
Abstract
Psoriasis is a chronic immune-mediated disease of a multifactorial nature, which has a decisive role in the development of genetic factors. Emerging evidence suggests a central role for IL-17 and IL-23/T17 in the pathogenesis of psoriasis, providing rationale for the use of IL-17 blocking agents as therapeutic agents. Most patients with psoriasis have concomitant comorbid pathology, which is a harbinger of the development of concomitant diseases. This fact must be taken into account when determining patient management tactics and developing new personalized treatment methods. The article provides a review of current literature data on the connection of psoriasis with various comorbid conditions and the key role of IL 17 in targeted therapy.
Full Text
About the authors
Oksana Ardalina
ФГБОУ ВО Саратовский Государственный медицинский университет им. В.И. Разумовского Минздрава РФ
Author for correspondence.
Email: ardalinaoo@mail.ru
ORCID iD: 0000-0002-9877-1262
SPIN-code: 6884-0480
ассистент кафедры дерматовенерологии и косметологии СГМУ
Russian Federation, 410028, Saratov, Proviantskaya St., 22, University Clinical Hospital No. 2 (Clinic of Skin and Venereal Diseases)References
- Олисова О.Ю., Гаранян Л.Г. Эпидемиология, этиопатогенез и коморбидность при псориазе – новые факты. Российский журнал кожных и венерических болезней. 2017; 20(4): 214-219. Olisova O.Yu., Garanyan L.G. Epidemiology, etiopathogenesis and comorbidity in psoriasis – new facts. Russian Journal of Skin and Venereal Diseases. 2017; 20(4): 214-219. [2] Ресурсы и деятельность медицинских организаций дерматовенерологического профиля. Заболеваемость инфекциями, передаваемыми половым путем, заразными кожными болезнями и болезнями кожи в 2023 году: статистические материалы/ И.А.Деев, О.С.Кобякова, А.А.Кубанов и др. Москва: ЦНИИОИЗ Минздрава России, 2024.- 208 с. [3] Рысбекова Д. Е. и др. Корреляционная связь между качеством жизни и тяжестью течения псориаза //Вестник Казахского Национального медицинского университета. – 2020. – №. 1. – С. 75-81. Rysbekova D. Ye. i dr. Korrelyatsionnaya svyaz' mezhdu kachestvom zhizni i tyazhest'yu techeniya psoriaza //Vestnik Kazakhskogo Natsional'nogo meditsinskogo universiteta. – 2020. – №. 1. – S. 75-81. [4] Rendon A., Schäkel K. Psoriasis pathogenesis and treatment //International journal of molecular sciences. – 2019. – Т. 20. – №. 6. – С. 1475. [5] Олисова О.Ю., Гаранян Л.Г. Коморбидности при псориазе. Российский журнал кожных и венерических болезней. 2016; 19(6): 346-348. Olisova O.YU., Garanyan L.G. Komorbidnosti pri psoriaze. Rossiyskiy zhurnal kozhnykh i venericheskikh bolezney. 2016; 19(6): 346-348. [6] Рыбалкин С.Б., Агейкин А.В., Агейкина К.А. Особенности выбора генно-инженерных биологических препаратов для лечения псориаза. Эффективная фармакотерапия. 2023; 19 (19): 64–68. Rybalkin S.B., Ageykin A.V., Ageykina K.A. Osobennosti vybora genno-inzhenernykh biologicheskikh preparatov dlya lecheniya psoriaza. Effektivnaya farmakoterapiya. 2023; 19 (19): 64–68. [7] Majumder S., McGeachy M. J. IL-17 in the pathogenesis of disease: good intentions gone awry //Annual review of immunology. – 2021. – Т. 39. – С. 537-556. [8] Соколовский Е. В. Переосмысление успеха терапии: лечение псориаза как системного заболевания //Эффективная фармакотерапия. – 2014. – №. 4. – С. 32. Sokolovskiy Ye. V. Pereosmysleniye uspekha terapii: lecheniye psoriaza kak sistemnogo zabolevaniya //Effektivnaya farmakoterapiya. – 2014. – №. 4. – S. 32. [9] Ion A. et al. Risks of Biologic Therapy and the Importance of Multidisciplinary Approach for an Accurate Management of Patients with Moderate-Severe Psoriasis and Concomitant Diseases //Biology. – 2022. – Т. 11. – No. 6. – С. 808. [10] Bonke, V.-KH. ; Bonke, S. ; Tobin, A.-M. ; Kirbi, B. «Psoriaticheskiy marsh»: kontseptsiya togo, kak tyazhelyy psoriaz mozhet privesti k serdechno-sosudistoy soputstvuyushchemu nasiliyu. Ekspress. Dermatol. 2011, 2020, 303–307. [11] Harper EG, Guo C, Rizzo H, Lillis JV, Kurtz SE, Skorcheva I, Purdy D, Fitch E, Iordanov M, Blauvelt A (2009) Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol 129: 2175–2183. [12] Chiricozzi A, Krueger JG (2013) IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs 22:993–1005. [13] Chiricozzi A, Nograles KE, Johnson-Huang LM, Fuentes-Duculan J, Cardinale I, Bonifacio KM, Gulati N, Mitsui H, Guttman-Yassky E, Suárez-Fariñas M, Krueger JG (2014) IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model. [14] Belasco J, Louie JS, Gulati N, Wei N, Nograles K, Fuentes-Duculan J, Mitsui H, Suárez-Fariñas M, Krueger JG (2015) Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis. Arthritis Rheumatol 67:934–944. [15] Suzuki E, Mellins ED, Gershwin ME, Nestle FO, Adamopoulos IE (2014) The IL-23/IL-17 axis in psoriatic arthritis. Autoimmun Rev 13:496–502. [16] Wang EA, Suzuki E, Maverakis E, Adamopoulos IE (2017) Targeting IL-17 in psoriatic arthritis. Eur J Rheumatol 4:272–277. [17] Miossec P, Kolls JK (2012) Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 11:763–776. [18] Neymann, A.L. ; Shin, D.B. ; Van, Iks. ; Margolis, DiDzhey ; Troksel', A.B. Gel'fand, Dzh.M. Rasprostranennost' serdechno-sosudistykh faktorov riska u patsiyentov s psoriazom. Dzh. YA. Akad. Dermatol. 20062006, 5555, 829-835. [19] Armstrong, A.V. ; Kharskamp, C.T. ; Armstrong, E.Dzh. Psoriaz i risk sakharnogo diabeta: sistematicheskiy obzor i metaanaliz. DZHAMA Dermatol. 20132013, 149149, 84-91. [20] Armstrong, A.V. ; Kharskamp, C.T. ; Armstrong, E.Dzh. Svyaz' mezhdu psoriazom i gipertoniyey: sistematicheskiy obzor i metaanaliz observatsionnykh issledovaniy. Dzh. Gipertens 2013, 3131, 433. [21] Dreyyer, Dzh. ; Vaytsman, D. ; Davidovovich, B. ; Shapiro, Dzh. ; Koen, A.D. Psoriaz i dislipidemiya: populyatsionnoye issledovaniye. Akta Derm. Venereol. 20082008, 8888, 561-565. [22] Pravenkumar, SSHA ; Ganguli, S. ; Rey, L. ; Nanda, S.K. ; Kuruvila, S. Rasprostranennost' metabolicheskogo sindroma u patsiyentov s psoriazom i yego otnosheniye k prodolzhitel'nosti zabolevaniya: issledovaniye, osnovannoye na bol'nichnom kontrole. Dzh. Klin. Diagnit. Res. 2016, 10, WC01-WC05. [23] Langan, S.M. ; Seminary, N.M. ; Shin, D.B. ; Troksel', A.B. ; Kimmel, S.E. ; Mekhta, N.N. ; Margolis, DiDzhey Gel'fand, Dzh.M. Rasprostranennost' metabolicheskogo sindroma u patsiyentov s psoriazom: populyatsionnoye issledovaniye v Velikobritanii. Dzh. Investiruyte. Dermatol. 2012 god, 132, 556–562. [24] Kimball, A.B. ; Sapari, P. ; Mrovits, U. ; Raykh, K. Lengli, R.G. ; Ty, YU. ; Khsu, MC. ; Usileniye, N. ; Reyder, DiDzhey. ; Mekhta, N.N. Nedostatochnaya diagnostika i nedostatochnaya obrabotka serdechno-sosudistykh faktorov riska u patsiyentov s umerennoy i tyazheloy formoy psoriaza. Dzh. YA. Akad. Dermatol. 2012201267, 67, 76-85. [25] Gaffen, S.L. ; Dzhayn, R. ; Garg, A.V. ; Kua, DiDzhey. Immunnaya os' Il-23-IL-17: ot mekhanizmov do terapevticheskogo testirovaniya. Net. Prepodobnyy. Immunol. 20142014, 1414, 585-600. [26] Sindzho, T. ; Ivashita, M. ; Yamasita, A. ; Sano, T. ; Tsuruta, M. ; Matsunaga, KH. ; Sanui, T. ; Asano, T. ; Nisimura, F. IL-17A sinergeticheski uluchshayet proizvodstvo TNFa-indutsirovannykh IL-6 i CCL20 v adipotsitakh 3T3-L1. Biokhim. Biofy. Res. Kommun. 2016, 477477, 241–246. [27] Yamauti, T. ; Kamon, Dzh. ; Minokoshi, I. ; Ito, YU. ; Vaki, KH. ; Uchida, S. ; Yamasita, S. ; Noda, M. ; Kita, S. ; Ueki, K.; i dr. Adiponetsin stimuliruyet ispol'zovaniye glyukozy i okisleniye zhirnoy kisloty putem aktivatsii AMF-aktivirovannoy AMF-aktivirovannoy proteinkinazy. Net. Med. 20022002, 88, 1288-1295. [28] Фейсханова Л.И., Лапшина С.А. Влияние секукинумаба на развитие дисфункции миокарда у пациентов с анкилозирующим спондилитом. РМЖ. 2020;11:49-53. Feyskhanova L.I., Lapshina S.A. Vliyaniye sekukinumaba na razvitiye disfunktsii miokarda u patsiyentov s ankiloziruyushchim spondilitom. RMZH. 2020;11:49-53. [29] Armstrong, A.V. ; Lin, S.V. ; Chembers, SiDzhey. ; Sokolov, M.Ye. ; Chin, D.L. Psoriaz i tyazhest' gipertonii: rezul'taty issledovaniya sluchay-kontrol'. PLoS ODIN 2011, 66, e18227. [30] Ena, P. ; Madeddu, P. ; Gloriozo, N. ; Tserimele, D. ; Rappelli, A. Vysokaya rasprostranennost' serdechno-sosudistykh zabolevaniy i povyshennaya aktivnost' renin-angiotenzinovoy sistemy u psoriaticheskikh bol'nykh. Akta. Kardiol. 19851985, 4040, 199–205. [31] Salekh, magistr nauk ; Norlander, A.Ye. ; Madkhur, MS. Ingibirovaniye interleykina 17-A, no ne interleykina-17F, signaliziruyushchego o snizhenii arterial'nogo davleniya i snizhenii vospaleniya konechnogo organa pri gipertonii, vyzvannoy angiotenzinom II. Bazovyy perevod JACC. Shitseps. 2016, 11, 606-616. [32] Vu, Dzh. ; Salekh, Magistr ; Kirabo, A. ; Itani, H.A. ; Montaniel, K.R.K. ; Syao, L. ; Chen', W. ; Merno, R.L. ; Tsay, KH. ; Bernstayn, K.Ye.; i dr. Immunnaya aktivatsiya, vyzvannaya okisleniyem sosudov, sposobstvuyet fibrozu i gipertonii. Dzh. Klin. Investiruyte. 2016, 126126, 50-67. [33] Khuan, L.-KH. Zinsel'meyyer, B.KH. ; Chang, K.-KH. ; Sonders, B.T. ; Elvington, A. ; Baba, O. Brokel'mann, Ti Dzhey. ; Tsi, L. ; Ruv, Dzh.S. ; Shvarts, magistr nauk; i dr. Interleykin-17 stimuliruyet interstitsial'noye zatyagivaniye lipoproteinov tkaney v eksperimental'nom psoriaze. Kletochnyy Metab. 2019, 2929, 475-487. [34] Amador, K.A. ; Barriyentos, V. ; Pen'ya, Dzh. ; Errada, A.A. ; Gonsales, M. ; Val'des, S. ; Karrasko, L. ; Al'zamora, R. ; Figeroa, F. ; Kalergis, A.M.; i dr. Spironolakton umen'shayet povrezhdeniye organov, vyzvannoye DOCA, blokiruya aktivatsiyu T-khelpera 17 i snizheniye regulyatsii regulyatornykh T-limfotsitov. Gipertoniya 20142014, 6363, 797–803. [35] Azfar, R.S. Gel'fand, Dzh.M. Psoriaz i metabolicheskiye zabolevaniya: epidemiologiya i patofiziologiya. Kurr. Mneniye. Revmatol. 20082008, 2020, 416-422. [36] Koto-Segura, P. ; Eyris-Sal'vado, N. ; Gonsales-Lara, L. ; Keyro-Silva, R. ; Martines-Kamblor, P. ; Mal'donado-Seral', K. ; Garsiya-Garsiya, B. ; Palasios-Garsiya, L. ; Gomes-Bernal, S. ; Santos-Khuanes, Dzh.; i dr. Psoriaz, psoriaticheskiy artrit i sakharnyy diabet 2 tipa: sistematicheskiy obzor i meta-analiz. Brent Dzh. Dermatol. 20132013, 169169, 783–793. [37] Li, I. ; Lyao, U. ; Chang, M. ; Shrodi, S.Dzh. ; Buy, N. ; Kataneze, Dzhey Dzhey. ; Pun, A. ; Matsunami, N. Kallis-Daffin, K.P. ; Leppert, M.F.; i dr. Dal'neyshiye geneticheskiye dokazatel'stva dlya trekh genov riska psoriaza: ADAM33, CDKAL1 i PTPN22. Dzh. Investiruyte. Dermatol. 20092009, 129129, 629–634. [38] Eyris, N. ; Gonsales-Lara, L. Santos-Khuanes, Dzh. ; Keyro, R. ; Koto, Ye. ; Koto-Segura, P. Geneticheskaya variatsiya pri IL12B, IL23R i IL23A svyazana s tyazhest'yu psoriaza, psoriaticheskim artritom i sakharnym diabetom 2 tipa. Dzh. Dermatol. Shitseps. 20142014, 7575, 167–172. [39] Friis, N.U. ; Khoffmann, N. ; Gildenlov, M. ; Skov, L. ; Vil'sboll', T. ; Nop, F.K. ; Storgordar, KH. Glyukoznyy obmen u patsiyentov s psoriazom. Brent Dzh. Dermatol. 2019, 180180, 264–271. [40] Bonke, S. ; Tachi, D. ; Beshmann, KH. Lyudvig, R.J. ; Akkermann, H. ; Badenkhup, K. ; Beynke, U. KH. U patsiyentov s psoriazom nablyudayutsya priznaki rezistentnosti k insulinu. Brent Dzh. Dermatol. 20072007, 157157, 1249-1251. [41] Maroof A, Smallie T, Archer S, Simpson C, Griffiths M, Baeten D, Shaw S (2017) Dual IL-17A and IL-17F inhibition with bimekizumab provides evidence for IL-17F contribution in immune-mediated inflammatory skin response. J Invest Dermatol 137:S120 [42] Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, vander Heijde D, Landewé R, Nash P, Pricop L, Yuan J, Richards HB, Mpofu S, FUTURE 1 Study Group (2015) Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl JMed 373:1329–1339. [43] Mease PJ, Genovese MC, Greenwald MW, Ritchlin CT, Beaulieu AD, Deodhar A, Newmark R, Feng J, Erondu N, Nirula A (2014) Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 370:2295–2306. [44] Пуиг Л., Бакулев А.Л., Кохан М.М. и др. Эффективность и безопасность нетакимаба, нового моноклонального антитела против IL-17, у пациентов с бляшечным псориазом средней и тяжелой степени. Результаты 54-недельного рандомизированного двойного слепого плацебо-контролируемого клинического исследования PLANETA. Дерматол Тер (Хейдельб) 11, 1319–1332 (2021). Puig, L., Bakulev, A.L., Kokhan, M.M. et al. Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial. Dermatol Ther (Heidelb) 11, 1319–1332 (2021).
Supplementary files
